Leiden, The Netherlands, April 2, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT™ platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.
Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“
Symposium: SY27 “New Cancer Vaccines“
Abstract number: SY27-01
Date: April 9, 2013, at 10:40 a.m.
Location: Room 202 at the Washington Convention Center.
The abstract is available at the AACR website www.aacr.org.
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is a biopharmaceutical company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company´s proprietary synthetic long peptide (SLP®) and AMPLIVANT™ platform permits the generation of safe and effective vaccines with a known mechanism of action. SLP® vaccines are broadly applicable to multiple targets and ideally suited as monotherapy or as essential components in combination with conventional cancer treatments.
Two SLP® vaccines are currently in clinical development: ISA101 is targeting human papillomavirus (HPV) induced diseases and ISA102 is targeting p53-overexpressing tumors. Clinical proof-of-concept has been established with ISA101 in Vulvar Intraepithelial Neoplasia (VIN), a pre-cancerous disease caused by HPV.
The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com
ISA Pharmaceuticals B.V.
Gerard Platenburg, Managing Director
J.H. Oortweg 19
2333 CH Leiden
Tel. +31 71 33 22 310
Dr. Ludger Wess, Ines-Regina Buth
Tel. +49 40 88 16 59 64, +49 30 23 63 27 68